58 reports

  • Target
  • Clinical Trial profile. 839 Trial Title

BIPOLAR DISORDER (MANIC DEPRESSION) THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* BIPOLAR DISORDER (MANIC DEPRESSION) THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* BIPOLAR DISORDER (MANIC DEPRESSION) TH

  • Clinical Trial
  • Hormone
  • Neurology
  • Type 2 Diabetes
  • World

The broad product portfolio includes many world leaders and a number of key products: Arimidex (cancer), Crestor (cardiovascular), Nexium (gastrointestinal disease), Seroquel (schizophrenia and bipolar disorder) and Symbicort (asthma and chronic obstructive pulmonary disease).

  • Hormone
  • China
  • AstraZeneca Pharmaceutical Co., Ltd
  • Bristol-Myers Squibb Company
  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  • Identifying factors impacting market growth

Melatonin supplements are also used to reset the circadian rhythm for other medical conditions such as AD, dementia, bipolar disorder (BP), COPD, and endometriosis, which affect the sleep cycle of people.

  • Hormone
  • World
  • Demand
  • Forecast
  • Reckitt Benckiser Group plc
  • Target
  • Target

ET) Poster EW##: Lurasidone Adjunctive to Lithium or Valproate for Prevention of Recurrence in Bipolar I Disorder (Monday, April ##, ##:##-##:## CET, ##:##-##:## a. m.

  • Clinical Trial
  • Hormone
  • Neurology
  • Type 2 Diabetes
  • World
  • 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Dormant Products
  • JNJ-18038683 - Drug Profile

Latuda is indicated for the treatment of patients with schizophrenia, as monotherapy for the treatment of patients with major depressive episodes associated with bipolar I disorder (bipolar depression), as adjunctive therapy with either lithium or valproate for th

  • Depression
  • Hormone
  • Pharmaceutical
  • United States
  • Product Initiative
  • Target
  • Clinical Trial profile. 68 Trial Title

Reddy' s under Fasting Conditions GDCT## NCT##, ##-## Central Nervous System Bipolar Disorder (Manic Depression), Depression, Major Depressive Disorder, Mania, Psychosis, Schizophrenia Completed Phase I Interventional olanzapine Dr.

  • Antipsychotic
  • Clinical Trial
  • Hormone
  • Hospital
  • Therapy
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database
  • Target

Results of a Depression and Bipolar Support Alliance Survey: Focused Analysis of Tardive Dyskinesia in Patients with Mood Disorders [P##-##][Poster Session ##May ##, ##:## p. m. -##:## p. m. ]

  • Hormone
  • Neurology
  • Type 2 Diabetes
  • World
  • Product Initiative
  • Target
  • Target

Reddy' s under Fed Conditions GDCT## NCT##, ## Central Nervous System Bipolar Disorder (Manic Depression), Psychosis, Schizophrenia, Schizophreniform Disorder Completed Phase I Interventional ziprasidone hydrochloride Dr.

  • Antipsychotic
  • Cardiovascular Drug
  • Clinical Trial
  • Hormone
  • Psychotic Disorder
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H1 2018
  • ENDOXIFEN - DRUG PROFILE

Jina Pharma is developing endoxifen for treatment of metastatic breast cancer and bipolar I disorder.

  • Breast Cancer
  • Contraceptive
  • Hormone
  • Hospital
  • Therapy
  • Target
  • Target

Reddy' s Laboratories Ltd ## Oct 2006 ## Oct 2006 ## ## ## ##-Hydroxytryptamine Receptor ##A (## HT##A or Serotonin Receptor ##A or HTR##A) Antagonist; D## Dopamine Receptor (Dopamine D## Receptor or DRD##) Antagonist ##-Hydroxytryptamine Receptor ##A (## HT##A or Serotonin Receptor ##A or HTR##A); D##

  • Clinical Trial
  • Hormone
  • Pharmaceutical
  • Therapy
  • World
  • Introduction
  • RP-5063 - DRUG PROFILE

RP## is also under development for the treatment of a brain disorders as from major depressive disorder (MDD), manic-depressive bipolar disorder, psychosis in Parkinson' s and Alzheimer' s diseases, autism and Tourette' s syndrome.

  • Hormone
  • Pharmaceutical
  • United States
  • Product Initiative
  • Reviva Pharmaceuticals Inc.
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

## ## ## ## Takeda Pharmaceutical Co Ltd ## ## ## ## ## Syri Ltd ## ## ## ## ## Pfizer Inc ## ## ## ## ## Johnson & Johnson ## ## ## ## ## Eli Lilly and Co ## ## ## ## ## Corcept Therapeutics Inc ## ## ## ##

  • Depression
  • Hormone
  • Hospital
  • World
  • Product Initiative
  • Introduction
  • RP-5063 - DRUG PROFILE

RP## is also under development for the treatment of a brain disorders as from major depressive disorder (MDD), manic-depressive bipolar disorder, psychosis in Parkinson' s and Alzheimer' s diseases, autism and Tourette' s syndrome.

  • Hormone
  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • Reviva Pharmaceuticals Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Anxiety Disorder
  • Hormone
  • World
  • Product Initiative
  • GlaxoSmithKline plc
  • Target
  • Target

ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* ATTENTION DEFICIT HYPERACTIVITY DISORDER

  • Clinical Trial
  • Hormone
  • Neurological Disorder
  • Neurology
  • Shire plc
  • Target
  • 5. All the trials included are unique trials.

PANIC DISORDERS THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* PANIC DISORDERS THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* PANIC DISORDERS THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* Company Name Phase IV

  • Anxiety Disorder
  • Hormone
  • Mental Health
  • Neurology
  • Therapy
  • ENDOXIFEN - DRUG PROFILE
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2018

IT IS IN PHASE III STAGE OF DEVELOPMENT FOR BIPOLAR DISORDER.

  • Breast Cancer
  • Hormone
  • United States
  • World
  • Product Initiative
  • FEMALE HYPOACTIVE SEXUAL DESIRE DISORDER - PIPELINE BY KUHNIL PHARMACEUTICAL CO LTD, H2 2018
  • FEMALE HYPOACTIVE SEXUAL DESIRE DISORDER - PIPELINE BY FABRE-KRAMER PHARMACEUTICALS INC, H2 2018

Its products are used for the treatment of various diseases such as central nervous system disorders, anxiety disorder, depression, hypoactive sexual desire disorder, Parkinson' s disease, erectile dysfunction, schizophrenia, social phobia, sexual dysfunction, bipolar

  • Hormone
  • Therapy
  • United States
  • Product Initiative
  • Palatin Technologies, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

CLINICAL TRIALS BY PHASE IN G## COUNTRIES BINGE EATING DISORDER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* BINGE EATING DISORDER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* BINGE EATING DISORDER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY

  • Clinical Trial
  • Eating Disorder
  • Hormone
  • Pharmaceutical
  • Shire plc
  • R&D Progress
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017 (CONTD..7), H2 2017

IT WAS ALSO UNDER DEVELOPMENT FOR MOOD DISORDER AND BIPOLAR DISORDER.

  • Hormone
  • Obesity
  • Therapy
  • Type 2 Diabetes
  • Omeros Corporation
  • 5. All the trials included are unique trials.

Hoffmann-La Roche Ltd Pfizer Inc Torrent Pharmaceuticals Ltd Phase IV Phase III Phase II/ III Phase II Phase I TOTAL ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Allergan Plc ## ## ## ## ## ## AstraZeneca Plc The Lundbeck Foundation Syneos Health Inc ## ## ##

  • Hormone
  • Neurology
  • Personality Disorder
  • Serotonin Specific Reuptake Inhibitor
  • Therapy
  • 5. All the trials included are unique trials.

GDCT ID is the unique ID of GlobalData' s Pharma Intelligence Center clinical trial database Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Collabora

  • Clinical Trial
  • Eating Disorder
  • Hormone
  • Neurology
  • Type 2 Diabetes
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Anxiety Disorder
  • Hormone
  • World
  • Product Initiative
  • Pfizer Inc.
  • Clinical Trial profile. 1087 Trial Title

CLINICAL TRIALS BY PHASE IN E## COUNTRIES SLEEP DISORDERS THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* SLEEP DISORDERS THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* SLEEP DISORDERS THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* Coun

  • Clinical Trial
  • Hormone
  • Type 2 Diabetes
  • World
  • Takeda Pharmaceutical Company Limited

## ## ## ## ## France ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## Canada Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a time p

  • Chronic Disease
  • Chronic Pain
  • Hormone
  • Musculoskeletal Disorder
  • Neurology

The broad product portfolio includes many world leaders and a number of key products: Arimidex (cancer), Crestor (cardiovascular), Nexium (gastrointestinal disease), Seroquel (schizophrenia and bipolar disorder) and Symbicort (asthma and chronic obstructive pulmonary disease).

  • Hormone
  • Pharmaceutical
  • Prostate Cancer
  • China
  • Demand
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Cardiology
  • Clinical Trial
  • Hormone
  • Therapy
  • Type 2 Diabetes
  • FEMALE SEXUAL DYSFUNCTION - PIPELINE BY ENDOCEUTICS INC, H1 2018
  • FEMALE SEXUAL DYSFUNCTION - PIPELINE BY EMOTIONAL BRAIN BV, H1 2018

Its products are used for the treatment of various diseases such as central nervous system disorders, anxiety disorder, depression, hypoactive sexual desire disorder, Parkinson' s disease, erectile dysfunction, schizophrenia, social phobia, sexual dysfunction, bipolar

  • Dysfunction Drug
  • Hormone
  • Type 2 Diabetes
  • United States
  • Palatin Technologies, Inc.
  • 5. All the trials included are unique trials.

CLINICAL TRIALS BY PHASE IN G## COUNTRIES POST MENOPAUSAL DISORDER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* POST MENOPAUSAL DISORDER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* POST MENOPAUSAL DISORDER THERAPEUTICS, G## COUNTRIES, CLINICAL

  • Hormone
  • Type 2 Diabetes
  • World
  • Product Initiative
  • Pfizer Inc.
  • TOLVAPTAN - DRUG PROFILE

Ltd. registered a Phase I dose block-randomized, double-blind, placebo-controlled, single dose, dose-escalation study to investigate the safety, tolerance, pharmacokinetics and pharmacodynamics of tolvaptan in healthy Korean male subjects bipolar disorder.

  • Hormone
  • Type 2 Diabetes
  • United States
  • Company
  • Product Initiative